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Prostate Speciﬁc Ets factor is a recently identiﬁed transcriptional activator that is overexpressed in prostate cancer. To
determine whether this gene is overexpressed in breast cancer, we performed a virtual Northern blot using data available
online at the Cancer Genome Anatomy Project website. Ninety-ﬁve SAGE libraries were probed with a unique sequence tag
to the Prostate Speciﬁc Ets gene. The results indicate that Prostate Speciﬁc Ets is expressed in 14 out of 15 breast cancer
libraries (93%), nine out of 10 prostate cancer libraries (90%), three out of 40 libraries from other cancers (7.5%), and four
out of 30 normal tissue libraries (13%). To determine the possibility that the Prostate Speciﬁc Ets gene is a novel marker for
detection of metastatic breast cancer in axillary lymph nodes, quantitative real-time RT–PCR analyses were performed. The
mean level of Prostate Speciﬁc Ets expression in lymph nodes containing metastatic breast cancer (n=22) was 410-fold higher
than in normal lymph node (n=51). A receiver operator characteristic curve analysis indicated that Prostate Speciﬁc Ets was
overexpressed in 18 out of 22 lymph nodes containing metastatic breast cancer (82%). The receiver operator characteristic
curve analysis also indicated that the diagnostic accuracy of the Prostate Speciﬁc Ets gene for detection of metastatic breast
cancer in axillary lymph nodes was 0.949. These results provide evidence that Prostate Speciﬁc Ets is a potentially informative
novel marker for detection of metastatic breast cancer in axillary lymph nodes, and should be included in any study that
involves molecular proﬁling of breast cancer.
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Given the heterogeneity of metastatic breast cancer, it is unlikely
that one breast cancer-associated gene will be overexpressed in all
disease tissues. We have shown that a multi-marker RT–PCR assay
can increase the sensitivity of metastatic detection (Mitas et al,
2001). There is also evidence that the use of multiple markers
may also increase the speciﬁcity of RT–PCR if more than one
marker must be positive for a positive test result (Houghton et
al, 2001; Hu and Chow, 2001). These data provide the impetus
to identify novel markers for the detection of metastatic breast
cancer.
Testing newly discovered genes that are potential diagnostic
markers for breast cancer is a time-consuming process; it requires
that gene-speciﬁc primers be designed, screened, and then validated
on a statistically signiﬁcant number of control normal and pathol-
ogy-positive tissues. In theory, the testing process could be
expedited if expression data for informative genes were available.
Fortunately, modern methods of genomics have recently produced
an unprecedented amount of expression data from normal and
cancer-associated tissues. As part of the Cancer Genome Anatomy
Project (CGAP), the National Center for Biotechnology Informa-
tion recently created a public website (http://www.ncbi.nlm.nih.
gov/ncicgap/) that allows users to compare computed gene expres-
sion proﬁles on-line between selected cDNA libraries, thus
generating a Digital Differential Display (DDD). Using DDD,
Scheurle et al (2000) recently compared breast cancer tissue with
others and concluded that mammaglobin 1 (mam1) was present
exclusively in breast cancer tissue. This conclusion is consistent
with our real-time RT–PCR results in which we discovered that
of 12 breast cancer-associated genes, mam1 had the highest diag-
nostic accuracy for metastatic disease in lymph node tissue (Mitas
et al, 2001). Scheurie et al, also concluded that with respect to
normal breast tissue, two genes that were the most signiﬁcantly
upregulated in breast cancer were Prostate Speciﬁc Ets factor
(PSE) and myosin light chain regulatory polypeptide 5 (MYL5).
In this study, we assessed the utility of PSE and MYL5 as
markers for quantitative real-time RT–PCR studies by ﬁrst
performing an on-line analysis of the SAGE library database avail-
able at the CGAP web site. Serial analysis of gene expression, or
SAGE, is designed to gain a direct and quantitative measure of
gene expression (Yamamoto et al, 2001). The SAGE method is
based on the isolation of unique sequence tags 9–10 bases in
length which are located immediately adjacent to the most 3'
CATG or GATC sequence of the mRNA. The tags are serially
concatenated into long DNA molecules and the sequence informa-
tion derived from them is deposited as a library into the SAGE
database maintained by the CGAP. Each of the 95 functional
libraries in the existing database can be compared to one another,
or alternatively, can be queried using unique sequence tags. The
output from such a query is obtained immediately, and the data
is expressed and normalised as number of sequence tags per
million library bases. This process represents a virtual Northern
blot (VNB) of various normal and cancer-associated tissues.
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www.bjcancer.comWe ﬁrst present VNB data that PSE, but not MYL5, is highly
overexpressed in breast cancer tissue. Using real-time RT–PCR,
we further demonstrate that PSE is highly expressed in four out
of ﬁve breast cancer cell lines. To determine the potential clinical
relevance of the PSE gene as a molecular diagnostic marker, we
analysed a panel of normal control lymph nodes (n=51), and axil-
lary lymph nodes (n=22) containing metastatic breast cancer. A
receiver operator characteristic curve analysis indicates that the
PSE gene is capable of detecting metastatic breast cancer in axillary
lymph nodes with high accuracy. This analysis also indicates that
PSE is overexpressed in 18 out of 22 lymph nodes containing meta-
static breast cancer, and in three out of 22 pathology-negative
lymph nodes from breast cancer patients. These results provide
strong evidence that PSE is a potentially valuable marker for detec-
tion of metastatic breast cancer in axillary lymph nodes and should
be integrated as a component of any multi-marker diagnostic assay.
MATERIALS AND METHODS
Virtual Northern blot
The cDNA sequences for the PSE and MYL5 genes (GenBank
accession numbers XM_004328 and NM_002477, respectively) were
used to identify sequence tags (UniGene cluster Hs.79414 for PSE
and Hs.170482 for MYL5) at the NCBI Virtual Northern blot
website (www.ncbi.nlm.nih.gov/SAGE/sagevn.cgi). The sequence
tags were then used to determine levels of expression in the 95
functional libraries in the SAGE database at the CGAP. NlaIII
was used as the anchoring enzyme.
Tissue specimens
Tissue specimens were obtained in accordance with federal and
institutional guidelines as previously described (Mitas et al,
2001).
Axillary lymph nodes from breast cancer patients Axillary
lymph nodes were obtained from breast cancer patients under-
going surgical therapy for the treatment of breast cancer.
Axillary lymph nodes were evaluated immediately by a surgical
pathologist at the time of specimen acquisition. For the purposes
of RT–PCR analysis, the lymph nodes were identiﬁed and
bisected. One portion was processed for real-time RT–PCR analy-
sis, and the other portion was sent for routine pathologic analysis.
Lymph node specimens destined for RT–PCR analysis were
immediately snap frozen in liquid nitrogen by the Hollings Cancer
Center (HCC) Tissue Procurement/Tissue Bank technician to
prevent RNA degradation. These nodes were stored at 7708C
in the HCC Tissue Bank until total RNA processing could be
performed.
Lymph nodes from patients without evidence of
cancer Lymph nodes were obtained from 51 patients undergoing
elective carotid endarterectomy. None of the patients had any
history or clinical evidence of cancer. At the time of the procedure,
a single cervical lymph node was removed and processed as noted
above.
Normal breast tissue Normal breast tissue specimens were
obtained from patients at St Vincent’s University Hospital (Ireland)
undergoing breast surgery for benign and malignant breast disease.
All tissue specimens were evaluated immediately at time of excision
by a surgical pathologist and normal breast tissue was identiﬁed. In
cases where the procedure was performed for malignant disease,
normal breast tissue was obtained from a part of the specimen at
least 3 cm from the malignant disease. Tissues were then snap
frozen in liquid nitrogen, stored at 7708C. Specimens were
shipped overnight to MUSC in dry ice.
RNA isolation
Total cellular RNA was isolated using a guanidium thiocynate-
phenol-chloroform solution as previously described (Mitas et al,
2001). Brieﬂy, a single tissue specimen was removed from
7708C storage and weighed as quickly as possible without allowing
the tissue to thaw. Tissue (0.15 gm) was then homogenised in
1.5 ml of a guanidium thiocynate-phenol-chloroform solution
(Tel-Test, Friendswood, TX, USA) using a model 395 type 5 poly-
tron (Dremel, Racine, WI, USA). Total RNA was then isolated as
per the manufacturer’s instructions. Final RNA pellets were
dissolved in 50 ml of DEPC treated water. RNA yield was deter-
mined by spectroscopy. Complementary DNA was made from
5 mg of total RNA using M-MLV reverse transcriptase (Promega,
Madison, WI, USA).
Determination of PSE intron/exon boundaries
To deﬁne the intron/exon boundaries of the PSE gene, its genomic
sequence (GenBank accession number AL157372) was aligned with
its cDNA sequence (GenBank accession number XM_004328) using
Blast 2 software (www.ncbi.nlm.nih.gov/BLAST/).
Real-time RT–PCR
Real-time RT–PCR was performed on a Gene Amp 5700 Sequence
Detection System (PE Biosystems, Foster City, CA, USA) as
previously described (Mitas et al, 2001). Brieﬂy, standard reaction
volume was 10 ml and contained 16 SYBR RT–PCR buffer,
3m M MgCl2, 0.2 mM each of dATP, dCTP, dGTP, 0.4 mM dUTP,
0.005 U AmpliTaq Gold, 0.002 U AmpErase UNG erase enzyme,
0.35 ml cDNA template, and 50–900 nM of oligonucleotide primer.
Initial steps of RT–PCR were 2 min at 508C for UNG erase activa-
tion, followed by a 10-min hold at 958C. Cycles (n=40) consisted
of a 15 s melt at 958C, followed by a 1 min annealing/extension
at 608C. The ﬁnal step was a 608C incubation for 1 min. All reac-
tions were performed in triplicate. Threshold for cycle of threshold
(Ct) analysis of all samples was set at 0.5 relative ﬂuorescence units.
The following primer pair for the PSE gene was used: forward,
AGTGCTCAAGGACATCGAGACG and reverse, AGCCACTTCTG-
CACATTGCTG.
For a given real-time RT–PCR sample, the point at which
ﬂuorescence starts to increase above background is referred to
as the cycle threshold (Ct) value. The Ct value is therefore
inversely proportional to the amount of speciﬁc mRNA species
in the original tissue sample. In our analyses, we normalised the
results to a reference control gene, b2-microglobin, to control for
RNA preparation. The result is termed the DCt value, in this
case the difference in Ct values for the PSE gene and the b2-
microglobin control gene. High DCt values are correlated with
low levels of gene expression whereas low DCt values are corre-
lated with high levels of gene expression. Relative PSE gene
expression levels in two samples can be derived from real-time
RT–PCR data using the equation (1+AE)
DDCt (PE Biosystems,
1998), where AE is the ampliﬁcation efﬁciency of the PSE gene,
and DDCt is the difference between DCt values from two cell/
tissue samples. To determine the AE of the PSE amplicon,
real-time RT–PCR studies were performed using serial 10-fold
dilutions of LNCaP cDNA using the formula AE=10
1/m-1
(Bieche et al, 1999), where m is the slope determined by linear
regression analysis.
Receiver operator characteristic (ROC) curve analysis of
cancer associated genes
Matched (control normal and metastatic breast cancer) data sets
were analysed using ROCKIT 0.9B Beta Version software (Metz et
al, 1998). Sensitivity and 1-Speciﬁcity values obtained from ROCKIT
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further analysis.
RESULTS
Virtual Northern blot of PSE gene
To investigate whether the PSE or MYL5 genes were overexpressed
in breast cancer, we performed a virtual Northern blot (VNB)
using an electronic database available at the CGAP website
(www.ncbi.nlm.nih.gov/SAGE/index.cgi). The cDNA sequences for
the PSE and MYL5 genes were used to identify reliable sequence
tags to the respective UniGene clusters Hs.79414 and Hs.170482.
The VNB revealed that two or more tags to the MYL5 gene were
present in only three prostate, one kidney, one brain, but no breast
(or other) libraries (data not shown). In contrast, two or more tags
to the PSE gene were identiﬁed in 14 out of 15 breast cancer
libraries (93%), nine out of 10 prostate cancer libraries (90%),
but only three out of 40 libraries from other cancers (7.5%), and
four out of 30 normal tissue libraries (13%) (Table 1). PSE was
detected in two out of two normal colon libraries (100%), and
two out of four normal prostate libraries (50%). No expression
of the PSE gene was observed in ﬁve normal breast tissue libraries.
The observation that PSE was expressed in colon tissue agrees well
with previous Northern blot results of Yamada et al (2000) who
showed that PSE was signiﬁcantly expressed in mouse prostate
and cecum, and to a minor extent in the oviduct, seminal vesicle,
stomach, and colon. The tissue expressing the highest level of PSE
(664 PSE tags per million (TPM) sequenced tags) was a lymph
node containing metastatic breast cancer (data not shown). For
comparison, this same tissue expressed b2-microglobin at a rate of
3320 TPM (data not shown). This highly expressed gene is often
used as an internal reference control for gene quantiﬁcation. The
observation that the rate of tag detection for PSE and b2-microglo-
bin genes differed only ﬁve-fold provides evidence that PSE is
highly overexpressed in at least some breast cancer tissues. The
results of the electronic screening analysis provided the impetus
to formally test PSE as a potential molecular marker of metastatic
breast cancer.
Identiﬁcation of a PCR primer pair speciﬁc for the PSE
gene
We designed four intron-spanning primers to the PSE gene using
Primer Express software. To validate the primers, we performed
real-time RT–PCR analyses using cDNA prepared from LNCaP,
a prostate cell line which has previously been shown to express
the PSE gene at high levels (Nozawa et al, 2000). Real-time RT–
PCR analyses were performed with SYBR Green I, a ﬂuorescent
dye that binds to double-stranded DNA (Schneeberger et al,
1995). With each of the four primer pairs, we observed that PSE
expression levels in LNCaP cells were comparable to the control
housekeeping gene, b2-microglobin (data not shown; in a typical
cell, b2-microglobin comprises 0.1–1% of the total mRNA). To
avoid potential ampliﬁcation of genomic DNA in subsequent
studies, we selected the primer pair that spanned the largest intron
(2.3 Kb; Figure 1). Using this primer pair and LNCaP cDNA, we
conﬁrmed ampliﬁcation of a speciﬁc product by obtaining the
following results: (1) on-line ﬂuorescence detection of ampliﬁca-
tion following cDNA preparation in the presence but not the
absence of reverse transcriptase, (2) the measured melting tempera-
ture (Tm) of the product (as determined by denaturation proﬁle
analysis) was 848C, a value within 28C of its calculated Tm
(838C), and (3) the sequence of the ampliﬁed fragment matched
the PSE cDNA gene sequence (data not shown). For all subsequent
real-time RT–PCR studies described in the text, speciﬁc ampliﬁca-
tion of the PSE cDNA was veriﬁed by denaturation proﬁle analysis.
PSE is highly expressed in various breast cancer cell lines
Relative expression of the PSE gene was determined in six breast,
two pancreatic, and three prostate cancer cell lines by real-time
RT–PCR analyses. Of the three prostrate cell lines examined, the
highest level of PSE expression was observed in LNCaP (DCt=0.6;
i.e., PSE was expressed at 2
70.6-fold (or 0.66) the level of b2-micro-
globin), whereas the lowest level was observed in DU145 (DCt=5.2;
Figure 2). In the two pancreatic cell lines, DCt values for the PSE
gene were relatively high (10.8 and 12.7), indicating that this gene
was expressed 990-fold lower, and 3600-fold lower respectively
than LNCaP. In two of the breast cancer metastatic cell lines,
DCt values for the PSE gene were lower compared to LNCaP
(70.3, MDA-453 and 0.25, MDA-361), indicating that high
expression of PSE is not restricted to prostate cancer. This result
conﬁrms the VNB data. Of interest, the DCt value for PSE was rela-
tively high (indicating poor expression) in MCF-10A, an
immortalised breast cancer cell line considered to have no meta-
static potential (Plopper et al, 1998).
PSE expression levels in normal lymph nodes and in lymph
nodes containing metastatic breast cancer
To assess the potential of PSE as a molecular marker for the detec-
tion of metastatic breast cancer, we performed analyses on an
extensive panel of control lymph nodes, normal breast tissue
samples, primary breast cancer samples, and lymph nodes contain-
ing metastatic breast cancer. We ﬁrst analysed 51 lymph nodes
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Table 1 Virtual Northern blot of PSE gene
Normal libraries Cancer libraries
Tissue pse+ Total % pse+ pse+ Total % pse+
Breast 0 5 0 14 15 93
Prostate 2 4 50 9 10 90
Colon 2 2 100 1 6 17
Ovary 0 2 0 1 10 10
Pancreas 0 2 0 1 6 17
Brain 0 7 0 0 18 0
Kidney 0 2 0 0 0 0
Skin 0 3 0 0 0 0
Vascular 0 2 0 0 0 0
Peritoneum 0 1 0 0 0 0
pointed
2 1 3 4 5 6
Ets Ets
Exon
5'-UTR 3'-UTR
Figure 1 Genomic structure of the PSE gene. Intron/exon boundaries of the PSE gene were obtained as described in Materials and Methods. The nucleo-
tide lengths of exons 1–6 are: 1 (386), 2 (465), 3 (198), 4 (48), 5 (146), 6 (650). Lengths (in nucleotides) of introns following respective exons are: 1
(11444), 2 (2338), 3 (1421), 4 (118), and 5 (797). Functional domains of the exons (Oettgen et al, 2000) are indicated in the top portion of the boxes.
Translation start site is indicated by arrow at far left of exon 2. Arrow at the top right of exon 2 indicates approximate position of forward primer used for
real-time RT–PCR analyses is indicated, while arrow below exon 3 indicates position of the reverse primer.
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DCt values ranged from 24.6 to 12.8 (mean=17.6), indicating that
PSE was expressed poorly or not at all in some patients, and at
detectable but low levels in others (Figure 2). In 22 lymph nodes
containing breast cancer, the DCt values varied from 17.0 to 2.0
(mean=8.9); the mean level of expression in metastatic tissue was
410-fold higher compared to normal lymph nodes. This result
conﬁrms the potential of PSE as a molecular marker for the detec-
tion of metastatic breast cancer. In six normal breast tissue
samples, DCt values for PSE ranged from 19.2 to 4.3
(mean=10.1+5.6), providing evidence that although the level of
expression of this gene varied in normal breast tissue samples, it
was generally higher than normal lymph nodes (mean level of
expression 160-fold higher). In 27 primary breast cancer samples,
DCt values for PSE ranged from 13.0 to 2.4 (mean=6.6+3.2).
Thus, the mean expression of PSE was increased 11-fold in primary
breast tumours compared to unmatched normal breast tissue.
To rigorously deﬁne the diagnostic value of the PSE gene, we
performed a receiver operator characteristic (ROC) curve analysis,
the most commonly used method for assessing the accuracy of
diagnostic tests (Henderson, 1993). ROC curve analysis is based
on a plot of sensitivity as a function of 1-speciﬁcity. The area
under the ROC curve (W) is a measure of diagnostic accuracy such
that values between 0.5 and 0.7 indicate low accuracy, values
between 0.7 to 0.9 indicate moderate accuracy and values greater
than 0.9 indicate high accuracy (Swets, 1988). With respect to
metastatic breast cancer, the diagnostic value of PSE was 0.949
(95% conﬁdence interval range=0.828–0.990), indicating that
PSE was highly accurate. Using a threshold corresponding to a
speciﬁcity value of 98%, we observed that 18 out of 22 (82%) of
the pathology-positive lymph nodes overexpressed PSE (Figure 2).
Detection of occult micrometastatic disease in breast
cancer patients
To determine whether PSE might prove useful for the detection of
occult micrometastatic disease in breast cancer patients, 22 axillary
lymph nodes from breast cancer patients without pathologic
evidence of metastatic breast cancer were analysed. Previous analy-
sis has revealed that of the 22 nodes, six overexpressed PIP, three
overexpressed mam, and one overexpressed CEA. We observed that
in three of the 22 samples (14%), PSE was overexpressed (Figure
2). All three samples in which PSE was overexpressed also overex-
pressed either mam or PIP (data not shown). In the remaining 19
samples, PSE was expressed at levels not considered signiﬁcantly
different from those observed in normal lymph nodes.
DISCUSSION
The goal of breast cancer staging is to classify patients by the extent
of disease into groups with similar clinical outcomes. Staging facil-
itates patient management, allowing clinicians to tailor therapies to
individual patients. The presence of metastatic disease in the axil-
lary lymph nodes (ALN) is considered the single most important
prognostic indicator for breast cancer patients, with an inverse rela-
tionship existing between the number of lymph nodes positive for
cancer and prognosis (Valagussa et al, 1978). As a result, staging
for newly diagnosed clinical Stage I and II breast cancer patients
has traditionally included an ipsilateral axillary lymph node dissec-
tion. Currently, routine pathologic analysis of axillary lymph nodes
in breast cancer patients consists of the preparation of one or two
sections from the central area of the node followed by staining with
hematoxylin and eosin and microscopic examination. However,
this procedure evaluates only a small portion of the node, and
studies have shown that serial sectioning and immunohistochemis-
try increase the sensitivity of detection of metastatic disease. The
presence of metastatic disease detected in this fashion has been
shown to be associated with decreased disease-free survival
(McGuckin et al, 1996). Although these techniques provide the
ability to detect clinically signiﬁcant metastatic disease, they are
extremely time-consuming and expensive, and are not used on a
routine basis. The current limitations of breast cancer staging
suggest that the successful development and validation of a sensi-
tive and speciﬁc molecular diagnostic assay is likely to have a
signiﬁcant clinical impact.
For negative controls, we used cervical (as opposed to axillary)
lymph nodes obtained during elective carotid endarterectomy.
Unfortunately, we did not have access to normal axillary lymph
nodes, which would have been more appropriate for this study.
Nonetheless, we feel that cervical lymph nodes served as a sufﬁcient
negative control for the genes described in this study. We base this
statement primarily on the distribution of DCt values in the control
negative and pathology-negative groups. In theory, if a given gene
is cancer- or tissue-speciﬁc, its distribution pattern should be such
that with the exception of a distinct subset of high expressing
samples in the pathology-negative group, expression patterns
should be otherwise identical between pathology-negative and
control normal groups. In support of this hypothesis, we observed
that the mean DCt value for PSE gene in the control normal group
was 17.7+2 .4, slightly lower (thus corresponding to higher expres-
sion) but not statistically different from the mean value in the
pathology negative lymph node group (18.7+2.3). In further
support, we observed that the pathology-negative group contained
four high expressing samples, whereas only one was observed in the
control normal group.
We have focused our attention in this study on PSE, a gene
known to be overexpressed in prostate cancer (Oettgen et al,
2000; Yamada et al, 2000). We ﬁrst performed a VNB of the CGAP
SAGE database and obtained compelling evidence that PSE is over-
expressed in various breast cancer tissues (Table 1). The results of
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Figure 2 Expression of PSE in cancer cell lines, breast tissue, and lymph
nodes. Real-time PCR analyses were performed using primers to the PSE
gene and various cell line or tissue samples described in Materials and
Methods. Ct values for each gene were determined from triplicate reac-
tions. DCt values were obtained by subtracting the mean Ct value of b2-
microglobin for the respective sample from the mean Ct value for PSE. Sym-
bols for the cell lines are: Pancreas: triangle, Panc1; open square, Capan1.
Prostate: open square, DUI145; X, LnCap; triangle, PC3. Breast: open circle,
MDA453; open square, MDA231; 7, MDA361; triangle, SkBr3; X, MCF7;
+, MCF10A. Number of samples analysed for each tissue: 51 negative con-
trol normal lymph nodes (solid circles=females, open triangles=males), 22
pathology-positive axillary lymph nodes (open square) and 22 pathology-
negative axillary lymph nodes (open diamond). Horizontal line indicates
DCt threshold value obtained at a 98% speciﬁcity level using the ROC
curve analysis described in the text.
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in electronic databases at the CGAP can be used to identify poten-
tially informative marker genes overexpressed in breast and other
cancers. In addition to the VNB analysis, the SAGE database can
be used to perform DDD where speciﬁc cDNA frequencies in
normal tissue and cancer-associated libraries are compared. For
example, Argani et al (2001) recently used the CGAP SAGE data-
base to identify genes that were differentially expressed between
pancreatic cancers and normal tissues. They determined that pros-
tate stem cell antigen was overexpressed in pancreatic cancer and
conﬁrmed this ﬁnding by subsequent RT–PCR and immunohisto-
chemistry analyses of primary pancreatic cancer specimens.
It is not clear whether PSE plays a role in the maintenance or
progression of breast cancer. PSE is a member of the Ets transcrip-
tional family. Ets proteins contain a conserved amino acid DNA
binding domain, function in the nucleus, have a short half-life,
and are present at low abundance in the cell (Watson et al,
1988; Seth et al, 1992; Janknecht and Nordheim, 1993; Wasylyk
et al, 1993). Despite overexpression of PSE mRNA in the prostate
cancer cell lines DU145, PC-3, and LNCaP, Nozawa et al (2000)
failed to detect by Western blot analysis any PSE protein in these
cell lines. This suggests that in prostate cancer, expression of the
PSE gene product is (i) controlled at the translational level and
(ii) not necessary for metastatic growth. We suspect that in breast
cancer, PSE protein is regulated in a similar manner and that over-
expression of PSE mRNA likely occurs as a consequence of
progression to a metastatic state but is not a causative factor. If this
proves to be the case, the gene product is not likely to be a clini-
cally useful therapeutic target.
One of the strengths of molecular diagnostic assays for the
detection of breast cancer is the ability to incorporate multiple
genetic markers into a single assay. We have already identiﬁed ﬁve
markers with moderate to high accuracy for the detection of breast
cancer as deﬁned by ROC analysis (Mitas et al, 2001). The use of
multiple markers has the potential to increase both the sensitivity
and speciﬁcity of these molecular diagnostic assays. The results
presented here conﬁrm this concept. We have previously analysed
17 of the 22 lymph nodes containing metastatic breast cancer
described here with a seven marker panel and have observed that
with the exception of one node, all others overexpressed at least
two cancer-associated genes (Mitas et al, 2001). The remaining
node marginally overexpressed mam1 (28-fold higher than normal
control lymph nodes). In this report, we observed that the same
node overexpressed PSE at a level 1.5610
5-fold higher than
normal control lymph nodes (data not shown). These results
suggest that PSE has the capacity to complement the markers that
we have previously identiﬁed.
We believe that real-time RT–PCR will signiﬁcantly improve
molecular diagnostic assays for the detection of breast cancer.
Traditional RT–PCR techniques are at best semi-quantitative,
and it has been difﬁcult to differentiate between baseline levels of
gene expression in normal tissues and increased levels of gene
expression associated with breast cancer, raising the concern for
false positive results. Real-time RT–PCR allows for the sensitive
detection and quantitation of gene expression and is quickly
becoming recognised as the technology of choice for the precise
measurement of gene expression levels (Bieche et al, 1998; Mitas
et al, 2001). The ampliﬁcation conditions for real-time RT–PCR
are also standardised, making this an ideal platform for high
throughput analysis of multiple markers. The standardised nature
of real-time RT–PCR also makes it possible to meaningfully
compare the diagnostic accuracy of different markers. In this study,
we analysed an extensive panel of control normal lymph nodes and
lymph nodes containing metastatic breast cancer. We determined
from ROC curve analysis that the diagnostic accuracy of the PSE
gene was 0.949, a value higher than six of the seven genes
previously identiﬁed as the best diagnostic markers for the detec-
tion of metastatic breast cancer ALNs (Mitas et al, 2001). These
results provide strong evidence that PSE is a potentially informative
novel marker, and should be a component of any multiple marker
diagnostic assay for detection of breast cancer.
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